Skip to main content
. 2022 Nov 2;10(11):e005414. doi: 10.1136/jitc-2022-005414

Figure 8.

Figure 8

Distribution of potential biomarkers at pretreatment and post-treatment in responders and non-responders for the treatment of combination of nivolumab and ipilimumab (arm A) in HCC patients. Statistical significance is calculated using Wilcoxon test. HCC, hepatocellular carcinoma; ns, not significant; ***, p<=0.001; ****, p<=0.0001.